Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Canada, Australia, and Ukraine. It also has a portfolio of established brands in cardiovascular, respiratory, dermatology, and non-opioid pain management. The company sells its products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey. Organon & Co. operates independently of Merck & Co., Inc. as of June 2, 2021.
IPO Year: 2021
Exchange: NYSE
Website: organon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/28/2026 | $14.00 | Underweight → Neutral | Piper Sandler |
| 12/9/2025 | $7.50 | Underweight | Barclays |
| 10/27/2025 | $5.00 | Overweight → Underweight | Piper Sandler |
| 5/2/2025 | Outperform → In-line | Evercore ISI | |
| 9/6/2024 | $18.00 → $20.00 | Neutral → Underweight | JP Morgan |
| 11/3/2023 | $33.00 → $16.00 | Buy → Neutral | Goldman |
| 9/21/2023 | $28.00 | Overweight | Barclays |
| 3/16/2023 | $33.00 | Outperform | Raymond James |
| 10/14/2022 | $27.00 → $25.00 | Neutral → Underperform | BofA Securities |
| 9/6/2022 | $37.00 → $34.00 | Neutral → Overweight | Piper Sandler |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Piper Sandler upgraded Organon from Underweight to Neutral and set a new price target of $14.00
Barclays initiated coverage of Organon with a rating of Underweight and set a new price target of $7.50
Piper Sandler downgraded Organon from Overweight to Underweight and set a new price target of $5.00
Evercore ISI downgraded Organon from Outperform to In-line
JP Morgan downgraded Organon from Neutral to Underweight and set a new price target of $20.00 from $18.00 previously
Goldman downgraded Organon from Buy to Neutral and set a new price target of $16.00 from $33.00 previously
Barclays initiated coverage of Organon with a rating of Overweight and set a new price target of $28.00
Raymond James initiated coverage of Organon with a rating of Outperform and set a new price target of $33.00
BofA Securities downgraded Organon from Neutral to Underperform and set a new price target of $25.00 from $27.00 previously
Piper Sandler upgraded Organon from Neutral to Overweight and set a new price target of $34.00 from $37.00 previously
PREM14A - Organon & Co. (0001821825) (Filer)
SD - Organon & Co. (0001821825) (Filer)
10-Q - Organon & Co. (0001821825) (Filer)
SCHEDULE 13G - Organon & Co. (0001821825) (Subject)
DEFA14A - Organon & Co. (0001821825) (Filer)
DEFA14A - Organon & Co. (0001821825) (Filer)
8-K - Organon & Co. (0001821825) (Filer)
DEFA14A - Organon & Co. (0001821825) (Filer)
DEFA14A - Organon & Co. (0001821825) (Filer)
DEFA14A - Organon & Co. (0001821825) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
4 - Organon & Co. (0001821825) (Issuer)
Fastest customizable press release news feed in the world
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women's health and general medicines portfolio Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women's health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect O
First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc
SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE:OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Unio
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC"). About Organon Organon (NYSE:OGN) is a global
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE:OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ "As the first, and currently the only, pertuzumab biosimilar in Europe, the EC's approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as
Organon stockholders to receive US$ 14.00 per share in cash The deal values Organon at EV of US$ 11.75 billion Combined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Organon & Co. (NYSE:OGN) ("Organon") today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press r
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the first quarter of 2026. Organon's first quarter results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing First Quarter 2026 Financial R
The American Academy of Dermatology (AAD) provided a strong, evidence-based recommendation for the use of VTAMA cream, the only steroid-free topical treatment the AAD found to be supported by a high certainty of evidence that is indicated across all severities in children aged 2 years and older with atopic dermatitis (AD) This recommendation reflects the proven efficacy, safety, and tolerability of VTAMA cream as a first-in-class, steroid-free, topical aryl hydrocarbon receptor (AhR) agonist for children and adolescents with AD AD, the most common form of eczema, impacts nearly 10 million children in the US Organon (NYSE:OGN), a global healthcare company with a mission to deliver
VTAMA demonstrated early and consistent response rates in disease severity and itch improvements, measured by the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) and Peak Pruritus-Numeric Rating Scale (PP-NRS) with results seen as early as week 1, and continued through week 8 Statistically significant ≥75% improvement in Eczema Area and Severity Index (EASI75) response was achieved as early as week 1 and continued through week 8 Improvements in Eczema Area and Severity Index (EASI) scores were achieved by the majority of patients (96.9%) from baseline at week 8 Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines a
Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia, Pennsylvania, on February 27, 2026. The findings show that VTAMA cream prov
Live Leadership Updates
Organon (NYSE:OGN) ("Organon" or "the company") today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Morrissey in his new role. Director Robert Essner will assume the role of Lead Independent Director. These appointments follow the resignation of Kevin Ali as Chief Executive Officer and member of the Board in connection with the Audit Committee investigation described below. Mr. Ali has agreed that he will not be entitled to severance o
Organon (NYSE:OGN) a global healthcare company with a focus on women's health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon's Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board's Talent Committee. In connection with Ms. Sequeira's appointment, the size of Organon's Board will be expanded to 12 directors. Ms. Sequeira brings more than 30 years of pharmaceutical industry expertise, with 20 years at Eli Lilly and Company and 10 years at Takeda. She is a proven commercial leader with a steadfast commitment to building strategies around the needs of patients and a trac
Leadership transition comes as Company focuses on clinical evaluation of its novel Ovarian Rebalancing™ technology, a one-time transvaginal ablation procedure designed to restore ovulation in women with PCOS, a leading cause of infertility PARIS, March 10, 2025 /PRNewswire/ -- May Health, a Paris- and California-based, clinical-stage medical device company dedicated to the development of a new treatment for Polycystic Ovary Syndrome (PCOS), today announced that Colby Holtshouse has joined the Company as President and CEO. Colby brings a wealth of senior leadership and women's health expertise to the organization, having held executive positions with Organon (NYSE:OGN), Alydia Health, and Pel
Organon Canada's operations are led by a diverse and highly capable team of equally represented men and women, offering a combination of relevant skills and experience, with a mission to deliver impactful medicines and solutions for a healthier every day for everyone, with a focus on women's health. KIRKLAND, QC, Oct. 8, 2024 /CNW/ - Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced updates to its Canadian leadership team with an appointment and promotion. Effective September 1, 2024, Jeffrey Malawsk
Organon Canada launches 'HER Professional Journey' to support female employees to navigate their career paths, and announces a new commitment to funding menopause-related education KIRKLAND, QC, March 8, 2024 /CNW/ - On International Women's Day, Organon Canada, a subsidiary of Organon (NYSE:OGN), a global healthcare company with a focus on women's health, launches HER Professional Journey and is encouraging businesses in Canada to Invest in HER and address the unique health experiences that women face, including in the workplace, so that women can feel supported and empowered at every stage of their career.
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the opening of trading on Wednesday, October 18: Lululemon Athletica Inc. (NASD:LULU) will replace Activision Blizzard Inc. (NASD:ATVI) in the S&P 500. S&P 500 and S&P 100 constituent Microsoft Corp. (NASD: MSFT) acquired Activision Blizzard in a transaction completed today, October 13. S&P MidCap 400 constituent Hubbell Inc. (NYSE:HUBB) will replace Organon & Co. (NYSE:OGN) in the S&P 500, S&P SmallCap 600 constituent Onto Innovation Inc. (NYSE:ONTO) will replace Hubbell in the S&P MidCap 400, and Organon & Co will re
Organon (NYSE:OGN), a global healthcare company with a focus on women's health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research, strengthening the company's global clinical and medical capabilities, advancing external relationships and fueling efforts to bring forward innovations to solve unmet health needs. Both positions report directly to Sandra Milligan, M.D., J.D., Head of Research and Development. Dr. Arjona Ferreira brings over two decades of clinical research and development experience and a strong background in women's health. Most recently, he was CMO
Weaver officially takes on role after becoming interim head of the Office of General Counsel and Corporate Secretary in July 2022 Organon (NYSE:OGN), a global women's healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon's executive leadership team, effective January 1, 2023. Mr. Weaver was named as the interim head of the Office of General Counsel and Corporate Secretary in July 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221212005040/en/Kirke Weaver (Photo: Business Wire) Mr. Weaver brings nearly 20 years of pharmaceut
Organon (NYSE:OGN), a global women's health company, today announced the appointment of Meghan Rivera as US Managing Director. With over 20 years of commercial experience in bio-pharmaceutical organizations and digital therapeutics, Ms. Rivera will be responsible for leading Organon's 400-strong US Commercial Operations team, maximizing growth potential across the company's portfolio of women's health, biosimilars, and established brands treatment areas. Ms. Rivera has significant commercial experience including roles in bio-pharmaceutical and digital therapeutic organizations and agency partners. She has extensive women's health expertise, having held leadership roles in commercial and ge
Live finance-specific insights
First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%. On April 26, 2026, the company announced its pending merger into Sun Pharmaceutical Industries Limited (together with its subsidiaries and/or associated companies, "Sun Pharma") in an all-cash transaction (the "merger"). The merger is expected to close in early 2027, subject to customary closing conditions, inc
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has canceled its first quarter 2026 earnings conference call previously scheduled for May 7, 2026. The cancellation is the result of the company's April 26, 2026 announcement that it has entered into an agreement under which Sun Pharmaceutical Industries Limited will acquire Organon. Organon will issue its first quarter financial results on April 30, 2026 in a press release, as well as in a subsequent Form 10-Q that it will file with the U.S. Securities and Exchange Commission ("SEC"). About Organon Organon (NYSE:OGN) is a global
Organon (NYSE:OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will release its first quarter 2026 financial results on May 7, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the first quarter of 2026. Organon's first quarter results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing First Quarter 2026 Financial R
Full year 2025 revenue of $6.2 billion, down 3% on both an as-reported basis and at constant currency Full year 2025 diluted earnings per share of $0.72 and non-GAAP Adjusted diluted earnings per share of $3.66 Full year 2025 Adjusted EBITDA of $1.91 billion inclusive of $6 million of IPR&D, representing a 30.7% Adjusted EBITDA margin The company expects to deliver approximately $6.2 billion of revenue and approximately $1.9 billion of Adjusted EBITDA for the full year 2026, both measures in-line with full year 2025 performance. Organon (NYSE:OGN) today announced its results for the fourth quarter and full year ended December 31, 2025. "In 2025 we took action that demonstrate
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its fourth quarter and full year 2025 financial results on February 12, 2026, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. IPR&D and Milestones Organon does not currently expect to record any milestone expense in the fourth quarter of 2025. Organon's fourth quarter and full year 2025 results have not been finalized and are subject to the company's quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein. Accessing Fourth Quarter and Full Year 2025 F
Third quarter 2025 revenue of $1.602 billion, up 1% as-reported and down 1% excluding the impact of foreign currency Third quarter 2025 diluted earnings per share of $0.61 and non-GAAP Adjusted diluted earnings per share of $1.01 Third quarter 2025 net income of $160 million and Adjusted EBITDA (non-GAAP) of $518 million, representing an Adjusted EBITDA margin of 32.3% Revenue guidance range for full year 2025 lowered to $6.200 billion to $6.250 billion; Adjusted EBITDA margin guidance lowered to ~31.0% Organon (NYSE:OGN) today announced its results for the third quarter ended September 30, 2025. "I am humbled to be working alongside our talented team during this pivotal time
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its third quarter 2025 financial results on November 10, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. ET. The webcast and conference call will be hosted by Carrie Cox, Organon's Executive Board Chair; Joe Morrissey, Interim Chief Executive Officer; and Matt Walsh, Chief Financial Officer. IPR&D and Milestones The company will not record any milestone expense in the third quarter of 2025. Accessing Third Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/inves
Second quarter 2025 revenue of $1.594 billion Second quarter 2025 diluted earnings per share of $0.56 and non-GAAP Adjusted diluted earnings per share of $1.00; GAAP diluted earnings per share includes a $46 million gain, or $0.14 per share, for early extinguishment of debt Second quarter 2025 net income of $145 million and Adjusted EBITDA (non-GAAP) of $522 million, representing an Adjusted EBITDA margin of 32.7% The company repaid $345 million of long-term debt during the quarter; on track to achieve a net debt to Adjusted EBITDA ratio of less than 4.0x by year-end Revenue guidance range for full year 2025 raised to $6.275 billion to $6.375 billion based on the company's curr
Organon (NYSE:OGN), a global healthcare company with a primary focus on women's health, will release its second quarter 2025 financial results on August 5, 2025, prior to the company's webcast and conference call scheduled for 8:30 a.m. EDT. Accessing Second Quarter 2025 Financial Results Webcast Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/events-and-presentations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company's website. Institutional investors and analysts interested in participating in the call may join by dialing (888) 596-4144
Company affirms full year 2025 financial guidance, resets dividend payout to strengthen capital structure Guidance ranges for full year 2025 revenue and Adjusted EBITDA margin are affirmed; company expects to generate over $900 million of free cash flow before one-time costs in 2025 Vtama on track to achieve $150 million revenue target for full year 2025; double-digit growth in Nexplanon in the first quarter Company resets capital allocation priorities to accelerate progress towards deleveraging; new annual regular dividend rate of $0.08 per share First quarter 2025 revenue of $1.513 billion, down 7% as-reported and down 4% at constant currency, consistent with company's expectation
This live feed shows all institutional transactions in real time.
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G - Organon & Co. (0001821825) (Subject)
SC 13G - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G/A - Organon & Co. (0001821825) (Subject)
SC 13G - Organon & Co. (0001821825) (Subject)